ENTX - רווח נקי למניה (EPS TTM) Entera Bio Ltd

Entera Bio Ltd. (ENTX) bases its generic defense on chemical patents for oral protein delivery. The TTM net income per share reflects current valuation trends, with the metric currently at -0.39. Strict FDA oversight and an IT platform for converting injections into tablets create high barriers to entry. The development is further complemented by the implementation of robotic modules to automate laboratory testing.

Investors are seeking fundamental drivers of stability by analyzing the real returns of the business. This metric is calculated by dividing the total annual net income by the total number of shares outstanding. The 12-month net income per share trend on this chart demonstrates the efficiency of capital management. For Entera Bio Ltd. (ENTX), this indicator reflects the financial success of commercializing oral drug delivery systems. Growth in this metric would confirm the profitability of implementing tablet forms of hormonal drugs.